Linked Life Data

17975488

Source:http://linkedlifedata.com/resource/pubmed/id/17975488

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2007-11-2
pubmed:abstractText
A large number of studies have indicated that thiazolidinediones (TZDs) such as rosiglitazone and pioglitazone inhibit tumor growth, progression, and metastasis. These agents are specific agonists for the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR gamma) but also engage other pathways. In lung cancer, these agents have been shown to induce apoptosis and inhibit tumor growth in xenograft models. Retrospective studies have indicated a significant decrease in lung cancer risk in patients using these agents, suggesting that TZDs may be chemopreventive for lung cancer. However, emerging data suggest that chronic use of these agents is associated with increased risk of adverse cardiovascular events. It is therefore critical to determine the relative contributions of PPAR gamma-dependent versus PPAR gamma-independent pathways in mediating both the anti-tumorigenic effects and the cardiovascular effects of TZDs. This review examines these pathways with a specific focus on the role of TZDs and PPAR gamma in lung cancer.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1556-1380
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
989-92
pubmed:dateRevised
2008-5-6
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors.
pubmed:affiliation
Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA. Raphael.Nemenoff@UCHSC.edu
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Extramural